Ultrasound radiogenomics, an emerging field at the intersection of radiology and genomics, employs high-throughput methods to convert radiological images into high-dimensional data, which are then processed to extract and analyze radiomic features. These features, including shape, texture, and intensity variations, are correlated with specific genetic mutations such as TP53 and PIK3CA, critical for cancer progression and treatment response. By integrating clinical data with ultrasonic features, predictive models are developed using machine learning techniques, aiming to refine the capability to diagnose and personalize treatment plans for breast cancer patients. This approach reduces the need for invasive biopsies and medical costs for patients through a better understanding of the tumor’s biological behavior using ultrasound images. This review focuses on the application of ultrasound radiogenomics for predicting gene mutations in breast cancer, highlighting its transformative potential in clinical practice and discussing ongoing challenges and future directions in this field.

As an emerging technology, radiomics has shown potential values in the field of healthcare. CT/MRI was preferred in previous radiomics researches because its images are easy to be standardized. And only until recently, an increasing number of studies focusing on the application of ultrasound radiomics in predicting molecular subtypes, identifying of malignant lesions, reactions to neoadjuvant chemotherapy, and axillary lymph node metastasis of breast cancer have been published. The purpose of this review is to summarize the steps of radiomics used in the field of breast cancer. In conclusion, ultrasound radiomics is a promising technology in diagnosing and monitoring breast cancer and further assisting physicians in patient management.